Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study
Cephalalgia · 2025
DOI: 10.1177/03331024251341243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2025. Verfasst von Sait Ashina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Understanding characteristics and reasons associated with using calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) for migraine prevention may help clinicians individualize treatment plans and achieve better patient outcomes.
Methods
We analyzed 2019–2020 cohort data of OVERCOME (US), a population-based survey among adults with migraine. Eligible participants were categorized based on current CGRP mAb usage (“NEVER” and “EVER” users [“Continued”, “Switched” and “Discontinued”]). Machine learning techniques followed by logistic regression were used to examine, among 60 sociodemographic, clinical, migraine-related- and migraine treatment utilization characteristics, those associated with CGRP mAb use status.
Results
Of 39,113 participants, 25.6% had ever used migraine preventive medication(s) and 5.0% used CGRP mAbs (of which 46.1% Continued, 14.7% Switched and 39.3% Discontinued). Top factors associated with higher odds of CGRP mAb EVER vs. NEVER use were currently using recommended acute medication (odds ratio (OR) = 2.43; 95% confidence interval (CI) = 2.09–2.82) and contraindications for triptan use (OR = 2.32; 95% CI = 2.06–2.60). Continuing use vs. switching or discontinuing was most associated with current use of botulinum toxin for migraine (OR = 2.21; 95% CI = 1.42–3.44 and OR = 4.53; 95% CI = 3.14–6.55, respectively).
Conclusions
At the time of survey, CGRP-targeted mAbs remain underutilized for migraine and multiple characteristics are associated with CGRP mAb use patterns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Value, Evidence and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.
- Medical Affairs, Eli Lilly and Company, Indianapolis, IN, USA.
- Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
ORCID-Profile: Sait Ashina, Gilwan Kim, Robert A Nicholson, Richard B Lipton
Zitieren
APA
Ashina, S., Kim, G., Muenzel, E. J., Buse, D. C., Zagar, A. J., Zakharyan, A., Shapiro, R. E., Nicholson, R. A., Pearlman, E. M., & Lipton, R. B. (2025). Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study. Cephalalgia. https://doi.org/10.1177/03331024251341243
Vancouver
Ashina S, Kim G, Muenzel EJ, Buse DC, Zagar AJ, Zakharyan A, et al. Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study. Cephalalgia. 2025. doi:10.1177/03331024251341243
BibTeX
@article{Ashina2025,
author = {Ashina, Sait and Kim, Gilwan and Muenzel, E Jolanda and Buse, Dawn C and Zagar, Anthony J and Zakharyan, Armen and Shapiro, Robert E and Nicholson, Robert A and Pearlman, Eric M and Lipton, Richard B},
title = {Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251341243}
}
EUVIMED